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Abstract
Background: Despite the frequency of diabetes mellitus and its relationship to diabetic peripheral neuropathy
(DPN) and neuropathic pain (NeP), our understanding of underlying mechanisms leading to chronic pain in
diabetes remains poor. Recent evidence has demonstated a prominent role of microglial cells in neuropathic pain
states. One potential therapeutic option gaining clinical acceptance is the cannabinoids, for which cannabinoid
receptors (CB) are expressed on neurons and microglia. We studied the accumulation and activation of spinal and
thalamic microglia in streptozotocin (STZ)-diabetic CD1 mice and the impact of cannabinoid receptor agonism/
antagonism during the development of a chronic NeP state. We provided either intranasal or intraperitoneal
cannabinoid agonists/antagonists at multiple doses both at the initiation of diabetes as well as after establishment
of diabetes and its related NeP state.
Results: Tactile allodynia and thermal hypersensitivity were observed over 8 months in diabetic mice without
intervention. Microglial density increases were seen in the dorsal spinal cord and in thalamic nuclei and were
accompanied by elevation of phosphorylated p38 MAPK, a marker of microglial activation. When initiated
coincidentally with diabetes, moderate-high doses of intranasal cannabidiol (cannaboid receptor 2 agonist) and
intraperitoneal cannabidiol attenuated the development of an NeP state, even after their discontinuation and
without modification of the diabetic state. Cannabidiol was also associated with restriction in elevation of
microglial density in the dorsal spinal cord and elevation in phosphorylated p38 MAPK. When initiated in an
established DPN NeP state, both CB1 and CB2 agonists demonstrated an antinociceptive effect until their
discontinuation. There were no pronociceptive effects demonstated for either CB1 or CB2 antagonists.
Conclusions: The prevention of microglial accumulation and activation in the dorsal spinal cord was associated
with limited development of a neuropathic pain state. Cannabinoids demonstrated antinociceptive effects in this
mouse model of DPN. These results suggest that such interventions may also benefit humans with DPN, and their
early introduction may also modify the development of the NeP state.
Background
Due to its recent epidemic, diabetes mellitus has
become the most common cause of peripheral neuropa-
thy worldwide, and approximately 50% of these patients
experience chronic neuropathic pain (NeP) [1]. The
mechanisms leading to NeP in diabetic peripheral
neuropathy (DPN) are likely multifold, but remain
poorly understood. As well, management of NeP in gen-
eral, including that associated with DPN, is inadequate
and unsatisfactory [2]. Of the current pharmacotherapies
for neuropathic pain, most are designed to block neuro-
transmission. This may limit their effectiveness as the
concomitant production of many inflammatory media-
tors continues to activate nociceptive neurons, contri-
buting to pain hypersensitivity. It has been
demonstrated that injuries and diseases of the nervous
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matory mediators within the spinal cord. Pro-inflamma-
tory cytokines such as interleukin-1beta (IL-1b),
interleukin-6 (IL-6), and tumor necrosis factor-alpha
(TNFa) are mainly produced by non-neuronal cells,
such as with glial cells in the spinal cord, [3,4] and play
an unchecked role in the creation of a neuropathic pain
state.
The knowledge of the prominent role of glial cells in
the development and maintenance of NeP has evolved
over the past decade. Both microglia and astrocyte acti-
vation is observed in the spinal cord following either
peripheral nervous system (PNS) or central nervous sys-
tem (CNS) injury [5-7]. Glial activation has also been
demonstrated in post-traumatic models, inflammatory
models [8-10], central demyelinating disorders [11,12],
and in diabetes mellitus [13-15]. Escalating evidence
suggests that glial cells in the spinal cord play an impor-
tant role in facilitation of pain [16,17], associated with
profound morphological changes in microglia [18].
Furthermore, glial inhibitors or glia modifying drugs
such as fluorocitrate and propentofylline can modify
pain sensitivity [19,20]. Microglia are regarded as a main
source of such inflammator ym e d i a t o r ss u c ha sI L - 1 b,
IL-6, and TNFa in the central nervous system [21,22].
Gene regulation following peripheral nervous system
injury is dramatically altered in spinal microglia [23],
who are also subject to proliferation [24]. Microglia also
express a number of plasma membrane receptors whose
activation ledas to microglial cell activation [4,25] and
migration [4,25]. However, the details of signaling mole-
cules triggerring microglial cell activation and migration
are poorly understood.
One important microglial system is the family of can-
nabinoid (CB) receptors and its endogenous ligands.
Endocannabinoids modulate microglial cell migration
without disturbing their ability to phagocytose particles
or produce nitric oxide. Although endocannabinoids,
including anandamide and 2-arachidonoylglycerol
(2-AG) [26], act upon CB1 and CB2 receptors are
secreted by neurons, they are more prominently pro-
duced in microglial cells during neuroinflammatory con-
ditions. 2-AG promotes recruitment of microglial cells
by ligation of CB2, but not CB1 receptors [26]. This is
likely due to CB1 receptors being expressed predomi-
nately at neurons in the central nervous system [27-29],
while the CB2 receptor is expressed predominately by
immune cells such as microglia [30]. Although both
CB1 and CB2 receptors are expressed in activated
microglial cells, their cellular expression is different,
with CB2 receptors abundantly expressed at the leading
edges of activated microglia [26].
Tetrahydrocannabinol (THC), a component in mari-
juana, acts at both CB1 and CB2 receptors, but other
forms of cannabinoids such as cannabinol and cannabi-
diol act predominantly at CB2 receptors. Such CB2 ago-
nists may be potential anti-inflammatory therapies [31],
antagonizing the 2-AG-induced recruitment of microglia
and impacting upon development of an inflammatory
state. Such properties may permit the cannabinoids to
act in the prevention of microglial activation, perhaps
limiting the development of neuropathic pain.
We examined clinically available pharmacotherapies
for neuropathic pain to identify impact upon microglial
activation in a model of chronic neuropathic pain. The
aims of our study were to identify the activation of
microglia in mice with diabetes and confirmed diabetic
peripheral neuropathy. Next, we examined whether CB2
receptor ligation could prevent microglial activation and
migration. Finally, we assessed CB1 and CB2 receptor
agonists/antagonists in the management of pain and
microglial activation in diabetic mice with long standing
diabetic neuropathy. We also sought to compare intra-
nasal delivery to intraperitoneal delivery of CB1 and
CB2 receptor antagonists since targeted intranasal direct
delivery to the CNS may be more beneficial in pain
management. Our hypotheses were: (1) microglia activa-
tion occurs in spinal cords and thalami of mice with
diabetes and painful diabetic peripheral neuropathy; (2)
CB2 receptor agonists would prevent microglial activa-
tion, ameliorating the development of neuropathic pain;
(3) CB1 agonists would benefit pre-existing neuropathic
pain in animals with long standing diabetic peripheral
neuropathy and associated pain. Our final goal was to
determine if nabilone, a synthetic commercially available
cannabinoid with CB1 and CB2 agonism activity was
beneficial in the diabetic peripheral neuropathy state
and could prevent the development of neuropathic pain
in this chronic disease state.
In order to specifically target the central nervous sys-
tem for activation of microglia, cannabinoid agents were
intranasally delivered to the brain. Intranasal delivery
was first developed to bypass the blood-brain-barrier
and directly target growth factors and other therapeutic
agents to the central nervous system [32] of rodents
[33-35] and humans [34,35] with delivery occurring
along both the olfactory and trigeminal neural pathways
using extracellular pathways rather than axonal trans-
port [34]. Previous studies have demonstrated that intra-
nasal delivery of cannabinoids achieves both central
nervous system and systemic concentrations comparable
with systemic delivery [33].
Methods
Animals
All experiments were carried out using male CD1 mice
(Charles River Laboratories), weighing 25-30 g at inita-
tion. All protocols were reviewed and approved by the
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Canadian Council of Animal Care guidelines. Experi-
mental study groups were randomized and behavioural
studies were performed by an experimenter who was
unaware of treatment groups.
In all cases, we studied CD1 male wildtype mice with
initial weight of 20-30 g housed in plastic sawdust covered,
pathogen-free cages with a normal light-dark cycle and
free access to mouse chow and water. CD1 mice were
selected due to lower rates of anticipated mortality in
long-term diabetic studies [36,37]. Mouse numbers were
selected to anticipate 25% and 40% mortality over the
course of 6 and 8 months of diabetes respectively. Mice
were anesthetized with pentobarbital (60 mg/kg) prior to
all terminal endpoints. At the age of 1 month, mice
intended to be diabetic were injected with streptozotocin
(Sigma, St. Louis, MO) intraperitoneally once daily for
each of three consecutive days with doses of 60 mg/kg, 50
mg/kg, and then 40 mg/kg, while mice intended to be
non-diabetic were injected with volume-matched carrier
(sodium citrate) for three consecutive days.
In all cases, whole blood glucose measurements were
performed monthly with puncture of the tail vein and a
blood glucometer (OneTouch Ultra Meter, LifeScan
Canada, Burnaby, BC, Canada). Hyperglycemia was veri-
fied 1 week after STZ injections, with a fasting whole-
blood glucose level of ≥ 16 mmol/l (normal 5-8 mmol/l)
being our definition for experimental diabetes. Mice that
did not meet these criteria for diagnosis of diabetes were
excluded from further assessment. All animals were
weighed monthly.
Intranasal and Systemic Delivery of Cannabinoid Agents
Intranasal delivery of the cannabinoid agents took place
over the indicated time points for each experiment.
While each mouse was held in supine position while in
neck extension, a total of 24 μl corresponding to doses
of each agent or 0.9% saline only was provided as four
drops of 6 μl each through an Eppendorf pipetter over
alternating nares every 1 minute. Intraperitoneal delivery
of either cannabinoid agents or 0.9% saline only was also
administered daily to either diabetic or non-diabetic
male CD1 mice as indicated with rotating sites used
over the abdomen for injections. Based upon our prior
experience with pharmacological delivery to the nervous
system [37,38], intranasal dosing was generally 1/10 that
of intraperitoneal dosing, which was selected based
upon published reports. We chose to use the low dose
intervention group as a control group for comparison to
higher doses of intranasal or intraperitoneal delivered
cannabinoid agents.
In order to determine appropriate infiltration of deliv-
ered cannabinoids to the nervous system, FITC fluores-
cence conjugation was performed (FluoroTag™ FITC
Conjugation Kit, Sigma-Aldrich Canada) and fluorescent
tagged molecules of cannabidiol and nabilone were
delivered through intranasal and intraperitoneal delivery
in 4 diabetic mice each, with surgical harvesting of brain
and spinal cord tissues of interest at 1, 6, and 24 hours.
An additional group of diabetic mice received unlabelled
saline both intranasally (n = 4) and intraperitoneally
(n = 4) for comparison.
Study Timelines, Animal Groups and Drug Administration
In Experiment 1, we first sought to study CD1 mice
with long term diabetes with comparison to non-dia-
betic littermates to determine expected levels of tactile
allodynia and thermal hyperalgesia as well as expected
levels of central nervous system microglial activation
(Figure 1). A total of 40 male CD1 wildtype mice were
induced diabetic while 25 male CD1 wildtype mice were
studied as citrate-injected control littermates over the
course of 8 months of diabetes (9 months of life) with-
o u td e l i v e r yo fa n yo t h e ra g e n t s .T h e s em i c ew e r es t u -
died with bimonthly sensory behavioral testing, and with
monthly sensory nerve conduction studies. Their spinal
cords were harvested after 1, 3, 5, and 8 months of dia-
betes for immunohistochemical and molecular
investigations.
In Experiment 2, we examined the impact of CB2
receptor activation or blockade upon microglial densities
in the central nervous system in the presence of painful
diabetic peripheral neuropathy. Life span in this experi-
ment was chosen to reflect the onset and duration of
neuropathic pain identified in Experiment 1. A total of
96 male CD1 wildtype mice were induced diabetic while
16 male CD1 wildtype mice were studied as citrate-
injected control littermates over the course of 4.5
months of diabetes (5.5 months of life). A total of 18
diabetic mice received intranasal cannabidiol (selective
CB2 agonist) (Cayman Chemical) [39] (n = 6, 0.1 mg/kg;
n = 6, 1 mg/kg; n = 6, 2 mg/kg) beginning at one week
after STZ injection when diabetes was confirmed with
this therapy continued for 3 months. Meanwhile, 18 dia-
betic mice received intranasal SR144528 (Aztra-Zeneca),
a selective CB2 receptor antagonist (n = 6, 0.01 mg/kg;
n=6 ,0 . 1m g / k g ;n=6 ,0 . 2m g / k g ) ,a g a i ns t a r t i n ga t
the time of confirmation of diabetes at 1 week post-STZ
injections for the duration of 3 months. In order to
examine the effect of CB2 receptor agonism in the pre-
sence of an established chronic neuropathic pain state,
an additional 6 diabetic mice received intranasal canna-
bidiol (2 mg/kg) and 6 diabetic mice received intranasal
SR144528 (0.2 mg/kg) beginning at 4 months of age
(3 months of diabetes) for one month. Intraperitoneal
delivery was performed for comparison of effect of
intranasal delivery. A total of 18 diabetic mice received
intraperitoneal cannabidiol (selective CB2 agonist)
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a total of 18 diabetic mice received intraperitoneal
SR144528 (n = 6, 0.1 mg/kg; n = 6, 1 mg/kg; n = 6, 2
mg/kg) for 3 months after confirmation of diabetes. An
additional 6 diabetic mice received intraperitoneal can-
nabidiol (20 mg/kg) and 6 diabetic mice received intra-
peritoneal SR144528 (2 mg/kg) beginning at 4 months
of age (3 months of diabetes) for one month for the
comparison to intranasally delivered groups. Age- and
sex-matched non-diabetic littermates were given either
intranasal saline at equal volumes (n = 4) or intraperito-
neal saline at equal volumes (n = 4) beginning at one
week following STZ injections for 3 months, or after
3 months of diabetes (n = 4 each) for one month.
During Experiment 3, we sought to determine the
impact of CB1 receptor ligation prior to and after estab-
lishment of a chronic neuropathic pain state. A total of
144 male CD1 wildtype diabetic mice and 16 male CD1
non-diabetic littermate wildtype mice were studied over
the course of 4.5 months of diabetes (5.5 months of life).
Figure 1 Timelines for experiments performed. Experiment 1 examined the natural history of nociception and microglial presence over 8
months of diabetes. Experiment 2 examined the intranasal and intraperitonel delivery of CB2 agonists/antagonists either at diabetes initiation or
after diabetic peripheral neuropathy-mediated neuropathic pain has initiated. Experiment 3 examined the intranasal and intraperitonel delivery of
CB1 agonists/antagonists (as well as one CB1 and CB2 agonist) either at diabetes initiation or after diabetic peripheral neuropathy-mediated
neuropathic pain has initiated.
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after STZ injections when diabetes was confirmed. A
total of 18 received intranasal nabilone solution (non-
selective CB1 and CB2 agonist) (Valeant Canada) (n = 6,
0.01 mg/kg; n = 6, 0.03 mg/kg; n = 6, 0.06 mg/kg) and a
total of 18 diabetic mice received intranasal WIN55212-2
(selective CB1 agonist) (Sigma Aldrich Canada) (n = 6,
0.01 mg/kg; n = 6 0.03 mg/kg; n = 6, 0.06 mg/kg), both
beginning at one week after STZ injection when diabetes
was confirmed and continued for 3 months. WIN55212-
2 has higher affinity than Δ
9-Tetrahydrocannabinol for
the CB1 receptor [40], but with a shorter half life. Eigh-
teen diabetic mice received intranasal delivery of the
selective CB1 cannabinoid antagonist SR141716A (GE
Healthcare) (n = 6, 0.01 mg/kg; n = 6, 0.1 mg/kg; n = 6,
0.2 mg/kg) beginning at confirmation of diabetes and
continued for 3 months. In order to examine the effect of
CB1 receptor agonism in the presence of an established
chronic neuropathic pain state, an additional 6 diabetic
mice received intranasal WIN55212-2 (0.06 mg/kg), 6
mice received intranasal nabilone (0.06 mg/kg), and 6
diabetic mice received intranasal SR141716A (0.2 mg/kg)
beginning at 4 months of age (3 months of diabetes) for
one month. Intraperitoneal delivery was again performed
for comparison of effect of intranasal delivery. Of the dia-
betic mice, a total of 18 received intraperitoneal nabilone
( n=6 ,0 . 0 1m g / k g ;n=60 . 3m g / k g ;n=6 ,0 . 6m g / k g )
while a total of 18 diabetic mice received intraperitoneal
WIN55212-2 (selective CB1 agonist) (n = 6, 0.01 mg/kg;
n = 6 0.3 mg/kg; n = 6, 0.6 mg/kg), each beginning after
diabetes confirmation and continued for 3 months. Eigh-
teen diabetic mice received intraperitoneal delivery of the
selective CB1 cannabinoid antagonist SR141716A (n = 6,
0.1 mg/kg; n = 6, 1 mg/kg; n = 6, 2 mg/kg) for the
3 months beginning after diabetes confirmation. An addi-
tional 6 diabetic mice received intraperitoneal
WIN55212-2 (0.6 mg/kg) and 6 diabetic mice received
intraperitoneal SR141716A (2 mg/kg) beginning at
4 months of age (3 months of diabetes) for one month
for the comparison to intranasally delivered groups. Age-
and sex-matched non-diabetic littermates were given
either intranasal saline at equal volumes (n = 4) or intra-
peritoneal saline at equal volumes (n = 4) beginning at
one week following STZ injections for 3 months, or after
3 months of diabetes (n = 4 each) for one month.
In all cases, animals were inspected for nasal conges-
tion, injection site infection, and for excessive sedation
on a daily basis. Weight was monitored monthly to
assess for cannabinoid-induced weight gain.
Behavioural testing
In all cases, baseline testing was done immediately prior
to STZ injections, and then immediately prior to canna-
binoid agent administration. During maintenance
therapy, behavioural testing was performed 12 hours
after the daily administration was performed. A mini-
mum of 1 hour was provided between forms of sensory
testing, and a minimum of 5 mice underwent beha-
vioural testing at each time point.
Mechanical Sensitivity
Mechanical withdrawal thresholds were tested using a
Dynamic Plantar Aesthesiometer (Ugo-Basile, Milan). In
brief, animals were placed in clear acrylic boxes (22 ×
16.5 × 14 cm) with a metal grid floor in a temperature
controlled room (22°C) and acclimatized for 15 min
before testing. The stimulus was applied via a metal fila-
ment (0.5 mm) which applied a linearly increasing force
ramp (2.5 g/s) to the plantar surface of the hind paw. A
cut-off of 50 g was imposed to prevent any tissue
damage. The force necessary to elicit a paw withdrawal
was recorded. The paw withdrawal threshold (PWT)
was calculated as the average of three consecutive tests
with at least 5 min between each test. Mechanical allo-
dynia was defined as reduced threshold after induction
of diabetes compared to a baseline PWT before STZ
injection.
Thermal Hyperalgesia
To quantitatively assess the thermal threshold of the
hindpaw, mice were placed on the glass surface of a
thermal testing apparatus with acclimatization for 30
minutes before testing. A mobile radiant heat source
(Hargreaves apparatus) located under the glass was
focused onto each of both hindpaws of each mouse.
A radiant heat source was applied individually to the
middle of either hindpaw for up to 60 seconds, with the
latency (seconds) to withdrawal measured. Heating rate
ramped from 30°C to 58°C over 60 seconds in consistent
fashion on each occasion. The cutoff of 60 seconds was
used to prevent potential tissue damage. Paws were
inspected before and after thermal testing to ensure that
no evidence of thermal damage was present. The with-
drawal latency of both hindpaws from three consecutive
trials was averaged, and the mean value was used as the
thermal threshold. There were 5 minute intervals pro-
vided between trials.
Electrophysiological testing
Electrophysiological assessment of sciatic nerve function
was performed as previously described [38] under
halothane anaesthesia. Initial baseline studies were car-
rier out prior to STZ or carrier injections. At least
4 mice in each intervention group underwent monthly
electrophysiological testing beginning prior to induction
of diabetes and after 1, 2, 4, 6, and 8 months of diabetes,
as possible. For orthodromic sensory conduction studies,
the sural nerve was used with a fixed distance of 30 mm
from platinum subdermal stimulation needle electrodes
(Grass Instruments, Astro-Med, West Warwick, RI) to
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to measure the sensory nerve action potential (SNAP)
amplitude and sensory nerve conduction velocity
(SNCV). Near-nerve temperature was kept constant dur-
ing testing at 37 ± 0.5°C using a heating lamp.
Surgical harvesting
Following 1, 3, 4.5, 5 or 8 months of diabetes, as indi-
cated, mice from each cohort were sacrificed using pen-
tobarbital intraperitoneal injections. A total of 0.5 ml of
whole intracardiac blood was obtained for HbA1C mea-
surements to be performed with latex agglutination inhi-
bition rate assay (Calgary Laboratory Services). The
following tissues were harvested: dorsal lumbar spinal
cord from L2-S1, and bilateral thalami. Left-sided tissues
were placed in 2% Zamboni’s fixative for later immuno-
histochemistry, while right-sided tissues were immedi-
ately fresh frozen at -80°C (Invitrogen, Burlington, ON)
and stored at -80°C for later protein identification.
Immunohistochemistry
After spinal cord and thalamus specimens were fixed in
2% Zamboni’s fixative overnight at 4°C, they were
washed in PBS, kept overnight in 25% glucose PBS solu-
tion, and then embedded in optimal cutting temperature
embedding solution, before storage at -80°C until sec-
tioning. Cryostat transverse and longitudinal nerve sec-
tions (10 μm) were placed onto poly-l-lysine and
acetone-coated slides. Antigen retrieval was performed
with slides placed in sodium citrate in an 80°C water
bath, a PBS wash for 5 min, blocking with 10% goat
serum for 1 h, and further PBS washing. In all cases,
slides were incubated with primary antibody overnight
at 4°C. After PBS washing, secondary fluorescent anti-
body was applied with incubation for 1 h at room tem-
perature, followed by PBS washing and slide mounting.
Primary antibodies used were goat anti-ionized cal-
cium-binding adaptor molecule 1 (Iba-1; 1:1000; Abcam,
Cambridge, MA) for microglial identification, rabbit
anti-cannabinoid receptor 1 antibody (CB1 receptor,
1:500, Sigma Aldrich Canada), rabbit anti-cannabinoid
receptor 2 antibody (CB2 receptor, 1:500, Sigma Aldrich
Canada), rabbit anti-phosphorylated p38 Mitogen Acti-
vated Protein Kinase (p-p38 MAPK; 1:100; Cell Signal-
ling Technology, USA), and rabbit anti-microtubule
associated protein-2 antibody produced in rabbit (MAP-
2, 1:500, M3696, Sigma Aldrich Canada) for neuronal
identification. Secondary antibodies used were either
anti-rabbit IgG fluorescein isothiocyanate (FITC)
labelled (1:100; Zymed, San Francisco, CA) or donkey
anti-goat IgG CY3 labeled (1:200, Fitzgerald Industries,
Concord, MA). Slides were cover-slipped with Vecta-
shield mounting medium (Vector Laboratories, CA,
USA) and visualised under a Zeiss Imager Z1 (Zeiss,
UK) fluorescence microscope. Iba-1, p-p38 and GFAP-
positive cells were determined by counting the number
of profiles (cell bodies).
Slides were examined under fluorescence microscopy
(Zeiss Axioskope, Axiovision and Axiocam, Zeiss
Canada, Toronto, Canada) at 200×. Calculation of the
number of immunofluorescent profiles as well as the
relative luminosity was performed using Adobe Photo-
shop (Adobe Photoshop 9.0, Adobe, San Jose, CA,
2005). In both thalamic and dorsal spinal cord regions,
the total numbers of microglia per transverse section, as
well as the numbers of microglia with positive immuno-
labelling for markers of interest. In the ventral postero-
lateral nucleus (VPL) ventral posteromedial (VPM) and
reticular (Rt) thalamic nuclei, microglia were identified
using Iba-1 immunohistochemistry, while tertiary neu-
rons were also identified using MAP-2 positivity along
with study of positive immunolabelling for markers of
interest. In the lumbar segment, the lateral, central and
medial dorsal horn regions, representing laminae 1-3,
were examined. When double immunolabelling was not
possible within a single specimen due to antibodies
deriving from identical species, consecutive slides were
instead used and overlapped. Luminosity was classified
as none-low (luminosity value of 0-150), moderate (150-
250) or high (>250) using Adobe Photoshop software
(scale of 0-255 with arbitrary units). For cellular densi-
ties, a box measuring 104 μm2 was placed onto areas of
dorsal horn for regions between L2 and S1 and within
thalamic nuclei of interest. A quantitative estimate (pro-
portional area) of changes in the activation state of
microglial cells was performed [41-43] in the VPL thala-
mic nucleus and dorsal spinal cord based on atlas
boundaries and after subtraction of background signal.
A resting microglia was classified as having a small,
compact soma with long, thin, ramified processes. Acti-
v a t e dm i c r o g l i a ,i nc o n t r a s t ,e x h i b i tm a r k e dc e l l u l a r
hypertrophy, and retracted processes with process length
less than soma diameter. Furthermore, microglia activa-
tion was assessed using a previously described qualita-
tive scale: - for baseline staining; + for mild response;
and ++ for moderate response [44]. All measurements
were performed by a single examiner blinded to the
group identity. A total of 25 randomly chosen areas of
dorsal spinal cord and thalamus, from a minimum of 4
animals per cohort group were examined.
Western Immunoblotting
Tissue portions from the dorsal spinal cord and thala-
mus were homogenized using a RotorStator Homoge-
nizer in ice-cold lysis buffer (10% glycerol, 2% SDS, 25
mM Tris-HCl, pH7.4, Roche Mini-Complete Protease
Inhibitors). Centrifugation of samples at 10,000G fol-
lowed for 15 minutes and equal amounts (15 μg) of
Toth et al. Molecular Pain 2010, 6:16
http://www.molecularpain.com/content/6/1/16
Page 6 of 22protein were separated by SDS-PAGE using 10% polya-
crylamide gels under conditions previously described
[38]. Blots were probed with Iba-1 (1:1000), CB1
(1:1000), CB2 (1:1000) and p-p38 MAPK (1:1000). For
housekeeping, anti-b-actin (1:100, Biogenesis Ltd.
Poole, UK) was applied to separate blots. Secondary
anti-rabbit, anti-mouse, or anti-human IgG HRP
Linked antibody (Cell Signaling) was applied at 1:5000
in each case as appropriate. Signal detection was per-
formed by exposing of the blot to enhanced chemi-
luminescent reagents (Amersham) for two minutes.
The blots were subsequently exposed and captured on
Kodac X-OMAT K film. In each case, three blots were
performed from different composites of mice, and ana-
lyzed with Adobe Photoshop (Adobe Photoshop 9.0,
Adobe, San Jose, CA, 2005) for semi-quantification of
blotting density.
Data analysis
Two-way repeated ANOVA measurements followed by
Tukey’s test were performed for analysis of behavioural
studies. We chose to analyze behavioral data based
upon comparison of either high or medium dosed inter-
vention to low dose of the same intervention. We also
chose to analyze behavioral data in mice with estab-
lished diabetes and late intervention with comparison to
diabetic mice who had received delivery of the same
agent and with the same route in early intervention stu-
dies. One-way ANOVA followed by Tukey’s test was
used for immunohistochemistry. Data collected in the
groups were expressed as mean ± standard error in all
cases. For immunohistochemistry comparisons
demonstrated as low/medium/high intensity, the indivi-
dual values were compared using unmatched ANOVA
testing.
Results
Experiment 1
Maintenance of Diabetes
After STZ injection, mice developed diabetes within 1
week in greater than 90% of animals, and in each case,
diabetes was maintained over the length of the study.
Diabetic mice were smaller than non-diabetic mice
within 1 month after STZ injection and diabetic mice
had smaller body weights throughout life (Table 1).
Mouse glycated haemoglobin was increased in all dia-
betic mice after 9 months of life (Table 1). The mortal-
ity rate in diabetic mice was significantly higher than in
non-diabetic mice (Table 1).
Development of Diabetic Peripheral Neuropathy and
Neuropathic Pain
Diabetic mice developed tactile allodynia and thermal
hyperalgesia at 7 and 9 weeks of diabetes respectively
(Figure 2). After approximately 23 weeks of diabetes,
hypersensitivity during these forms of testing disap-
peared in diabetic mice, and was followed by relative
hyposensitivities. Electrophysiological testing demon-
strated a loss of sensory nerve action potential ampli-
tude and slowing of sensory nerve conduction velocity
after 3 and 2 months of diabetes respectively (Figure 2).
Development of Increased Microglial Density and Activation
Microglial quantification over the duration of diabetes
identified increased microglial density in the dorsal
spinal cord regions after 3 and 5 months of diabetes
Table 1 Murine weights, fasting glycemia levels, glycated haemoglobin levels, and survival numbers in diabetic and
non-diabetic mice
Timepoint Injection of STZ/
Carrier
Month 1 Month 3 Month 5 Month 8
Murine Weight
Non-Diabetic Mice 25.9 +/- 2.8 (n = 25) 33.8 +/- 3.8 (n = 20) 34.7 +/- 3.8
(n = 15)
41.9 +/- 3.9*
(n = 10)
46.8 +/- 4.2* (n = 5)
Diabetic Mice 26.1 +/- 3.2 (n = 40) 26.9 +/- 4.2 (n = 33)
(2 non-diabetic)
28.4 +/- 4.3
(n = 26)
30.6 +/- 5.7
(n = 18)
31.5 +/- 5.8 (n = 6)
Murine Glycemia and 8
Month HbA1C
Injection of STZ/
Carrier
Month 1 Month 3 Month 5 Month 8 (Numbers in brackets indicate
glycated haemoglobin levels)
Non-Diabetic Mice 5.4 +/- 2.2 5.7 +/- 2.6 6.0 +/- 2.6 6.1 +/- 3.2 6.4 +/- 3.1* (5.4% +/- 1.8%)
Diabetic Mice 5.5 +/- 2.0 32.1 +/- 5.3 32.5 +/- 5.1 32.4 +/- 5.8 32.6 +/- 5.4 (14.7% +/- 2.1%)
&
Murine Survival Numbers Injection of STZ/
Carrier
Month 1 Month 3 Month 5 Month 8
Non-Diabetic Mice 25/25 (100%) 20/20 (100%) 15/15 (100%) 10/10* (100%) 5/5 (100%)*
Diabetic Mice 40/40 (100%) 33/33 (2 non-
diabetic, 100%)
26/30 (87%) 18/25 (72%) 6/20 (30%)
All measures are mean +/- SEM for weights, glycemia levels, and haemoglobin A1C levels. * indicates significance at p < 0.05 with comparison of non-diabetic
and diabetic mice cohort groups for weight and glycemic measures (non-matched ANOVA tests, F-values range between 5.68-137.9 for indicated groups and
time points, DF ≥ 7,4, n ≥ 5-10 at each time point as indicated. Glycated haemoglobin values are presented in italics in the 8 month column for glycemia levels.
Note that 5 diabetic and non-diabetic mice were harvested each month as per protocol) or for survival (Kaplan-Meier Survival statistics, n values indicated).
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Page 7 of 22when compared to non-diabetic specimens (Table 2).
Interestingly, there was a fall in microglial density after
8 months of diabetes, but diabetic specimens still main-
tained greater microglial quantities than non-diabetic
specimens. In the thalamic regions, increased microglial
density did occur after 5 months of diabetes, but was
not identified at other time points; the extent of
increased microglial density was considerably smaller
than in the dorsal spinal cord regions. Iba-1 protein
expression increased over time in diabetic spinal cord
specimens (Figure 3) as compared to non-diabetic speci-
mens. There was a non-significant trend towards
increased levels of CB1/CB2 receptor expression in dia-
betic spinal cord specimens over time, while p-p38
Figure 2 Tactile (A) and thermal (B) sensory testing data mice with or without diabetes. Significant differences were detected between
the diabetic mouse and non-diabetic mouse groups (non-matched ANOVA tests, F-values range between 6.18-9.72 for indicated groups and
time points, n ≥ 5, p < 0.05). Area under the curve (AUC) measurements were also significantly different between for the first 21 weeks of study
(p < 0.05) [n = 5-10 mice in each mouse cohort for each time point]. Diabetic mice have a significant loss of sensory nerve action potential
(SNAP) amplitudes (C) and sensory nerve conduction velocity (SNCV) (D) when compared to the non-diabetic mouse cohorts (non-matched
ANOVA tests, F-values range between 2.13-5.88 for indicated groups and time points, n ≥ 5, p < 0.05) after 2-3 months of diabetes [n = 4-6 mice
in each mouse cohort for each time point].
Table 2 Quantitative and qualitative analysis of microglia density within the dorsal horn and thalamus after indicated
time points of diabetes
Mouse Cohort Microglial Density in Ventral Lumbar Spinal Cord (number/mm
2)
1 Month 3 Months 5 Months 8 Months
Non-Diabetic 167.3 ± 14.9 (-) 154.1 ± 11.3 (-) 142.1 ± 15.8 (-) 139.2 ± 13.4 (-)
Diabetic 183.8 ± 16.7 (-) 227.5 ± 14.2* (+) 308.4 ± 19.6* (+) 256.4 ± 22.5* (+)
Microglial Density in Thalamic Nuclei (number/mm
2)
1 Month 3 Months 5 Months 8 Months
Non-Diabetic 108.6 ± 10.2(-) 104.3 ± 9.8(-) 101.2 ± 9.6 (-) 99.5 ± 8.4 (-)
Diabetic 113.2 ± 12.4(-) 123.0 ± 11.4 (+/-) 128.3 ± 10.1* (+/-) 116.3 ± 13.7 (-/+)
All measures are mean +/- SEM for microglial densities. * indicates significance at p < 0.05 with comparison of non-diabetic and diabetic mice cohort groups
(non-matched ANOVA tests, F-values range between 1.08-13.9 for indicated groups and time points, DF ≥ 7,4, n ≥ 4 at each time point. Microglial activation is
indicated using a qualitative scale: - for baseline staining; + for mild response; and ++ for moderate response, with the statistical mode response indicated in
brackets, or where two values were similar, the greater response is shown in front of the second most common value.
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Page 8 of 22Figure 3 During 8 months of diabetes, Western blotting (A) identified mild increasing levels of Iba1 (B), beginning at 3 months of
diabetes, when compared to non-diabetic littermates. As well, phosphorylated p38 MAPK elevates during diabetes until 5 months of time
(C). Sample protein blots are demonstrated in A from a total of 3 sample blots identified for each marker and each time point. Multiple ANOVA
tests were performed in each case, with * indicating significant difference (p < 0.05) between diabetic and non-diabetic cohorts.
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Page 9 of 22MAPK expression elevated during the course of diabetes
until the final time point when it declined (Figure 3).
There were no increases in comparative protein levels
within the diabetic thalamus (data not shown).
We identified sufficient changes to indicate microglial
activation in the diabetic dorsal spinal cord and lesser
degrees of activation with the diabetic thalamus to pro-
ceed to further manipulation of the CB1/CB2 receptor
system.
Experiment 2
Diabetic mice were again smaller than non-diabetic mice
within 1 month after STZ injection regardless of canna-
binoid agent delivery. There was a non-significant trend
towards larger weights in diabetic mice treated with
intranasal or intraperitoneal cannabidiol. Mouse glycated
haemoglobin levels remained increased in all diabetic
mice after more than 9 months of life and were
unchanged with cannabinoid agent delivery. Electrophy-
siological changes developed as witnessed in Experiment
1, without cannabinoid agents influencing the severity of
electrophysiological changes developing with diabetes
(data not shown). No systemic adverse effects were
identified, and there was no excessive sedation detected
to impact upon movement or food ingestion in any
group.
Fluorescently tagged cannabidiol was visualized in the
thalamus after 1 and 6 hours and in the dorsal spinal
cord after 6 and 24 hours (Figure 4) post-delivery when
compared to saline delivery.
Assessment of Neuropathic Pain
Diabetic mice receiving intranasal cannabidiol at moder-
ate or high doses beginning at onset of diabetes or
receiving intraperitoneal high dosing were subject to
alleviation of development of thermal hypersensitivity
and tactile allodynia. This effect was maintained during
cannabidiol delivery and for the additional four assess-
ments over 2 months following discontinuation of can-
nabidiol (Figure 5). Meanwhile, diabetic mice receiving
intranasal or intraperitoneal SR144528 at the onset of
diabetes had no measureable effect upon the develop-
ment of either thermal hypersensitivity or tactile
Figure 4 Fluroescent labeled cannabidiol (A) was visible within diabetic mouse thalamus 6 hours after delivery, with saline
intervention leading to no comparable fluorescence (B). Fluroescent labeled nabilone (C) was also visible within diabetic dorsal spinal cord
6 hours after delivery, with saline intervention leading to no comparable fluorescence (D). Bar = 10 μm.
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Page 10 of 22Figure 5 Tactile (A) and thermal (B) sensory testing data for diabetic mice receiving either intranasal or intraperitoneal cannabidiol at
low, medium, or high dose, with comparison to non-diabetic mice and saline delivery. Diabetic mice receiving medium or high doses of
intranasal or intraperitoneal cannabidiol had amelioration of both tactile allodynia and thermal hyperalgesia after 7 weeks when nociceptive
behaviors began. This protection against the development of the neuropathic pain state was also noted continually after the stoppage of
cannabidiol at week 14. For both tactile (A) and thermal (B) testing, significant differences were detected between the diabetic mouse group
receiving medium (g) or high doses (θ) of intranasal cannabidiol or high (Ψ) doses of intraperiteonal cannabidiol when compared to the diabetic
mouse group receiving low dose intranasal or intraperitoneal cannabidiol respectively (non-matched ANOVA tests, F-values range between 0.88-
4.13 for indicated groups and time points, n ≥ 4, p < 0.05). Area under the curve (AUC) measurements were also significantly different between
the same comparison groups in each case (p < 0.05). [n = 4-10 mice in each mouse cohort for each time point].
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Page 11 of 22allodynia (Figure 6). In mice with established neuro-
pathic pain due to diabetic peripheral neuropathy,
neither intranasal/intraperitoneal cannabidiol nor
SR144528 had any effect upon already present
and chronic thermal hypersensitivity or tactile allodynia
(Figure 7).
Development of Increased Microglial Density and Activation
Those mice receiving medium or high doses of intrana-
sal/intraperitoneal cannabidiol demonstrated lower den-
sities of microglia in the dorsal spinal cord (Table 3,
Figure 8) at endpoint. Expression of p-p38 MAPK was
also diminished in these mice. Diabetic mice receiving
intranasal/intraperitoneal SR144528 had no detectable
changes in microglia density or p-p38 MAPK expres-
sion. Qualitative assessment of microglial activation
revealed no definite differences between cohort groups.
Western blotting confirmed lower levels of both Iba-1
and p-p38 MAPK protein expression in the dorsal spinal
cord (Figure 8) of mice who received cannabidiol at dia-
betes onset. There were no changes in microglial density
or protein expression identified with interventions for
thalamic tissue specimens. There were also no observed
changes in microglial density or protein expression
when late interventions were provided to mice with long
standing diabetes.
Experiment 3
As in Experiment 2, diabetic mice were smaller than
non-diabetic mice, and had characteristic electrophysio-
logical changes and elevated HbA1C at endpoint; these
measures were unchanged with cannabinoid agent deliv-
ery (data not shown).
Fluorescently tagged nabilone was also visualized in
the thalamus after 1 and 6 hours and in the dorsal
spinal cord after 6 and 24 hours (Figure 4) post-delivery
when compared to saline delivery.
Assessment of Neuropathic Pain
Diabetic mice receiving intranasal/intraperitoneal nabi-
lone or WIN55212-2 solution in moderate-high doses at
onset of diabetes demonstrated alleviation of both tactile
allodynia and thermal hyperalgesia (Figure 9). This
dose-dependent benefit was only observed during the
weeks of nabilone or WIN55212-2 delivery, and tactile
allodynia and thermal hyperalgesia of greater magnitude
developed in the weeks following discontinuation of
nabilone. In contrast, intranasal/intraperitoneal
SR141716A delivery failed to impact upon the develop-
ment of tactile allodynia or thermal hyperalgesia in any
amount (data not shown). No systemic adverse effects
were identified, and no excessive sedation was noted to
impact upon movement or food ingestion.
In mice with chronic diabetic peripheral neuropathy
and established neuropathic pain, high dose intranasal/
intraperitoneal nabilone or WIN55212-2 partially
alleviated existing tactile allodynia and thermal hyperal-
gesia, but there was no observed effect with any inter-
vention using SR141716A (Figure 10).
Development of Increased Microglial Density and Activation
Despite transient improvement in neuropathic pain
measures, diabetic mice receiving intranasal/intraperito-
neal nabilone, WIN55212-2, or SR141716A had no dif-
ferences noted for microglial densities (Table 3) and no
visible changes in protein expression of Iba-1 or p-p38
MAPK within the dorsal spinal cord (Figure 11). There
were no identified changes in microglial density or pro-
tein expression for mice receiving interventions within
thalamic tissue specimens. There were also no observed
changes in microglial density or protein expression
when late interventions werep r o v i d e dt om i c ea f f e c t e d
by long standing diabetes.
Discussion
STZ-induced diabetes and subsequent tactile allodynia/
thermal hypersensitivity can be ameliorated with CB1
and CB2 receptor agonists. In addition, the CB2 agonist
c a n n a b i d i o lp r o v i d e da tt h eo n s e to fd i a b e t e sa n dp r i o r
to identified neuropathic pain limited the development
of later neuropathic pain and prevented increases in
microglial density. These results verified our hypothesis
that CB2 receptor ligation prevents microglial accumula-
tion after development of a neuropathic pain state,
although we did not identify any obvious differences in
qualitative assessment of microglial activation nor differ-
ences in electrophysiological detection of diabetic neuro-
pathy. Along with smaller numbers of accumulated
microglia, we observed an increase in the phosphory-
lated form of p38 MAPK which was diminished in dia-
betic mice receiving CB2 receptor agonist, suggesting a
more limited state of microglial activation. Meanwhile,
provision of higher doses of CB1 agonists were effective
in relieving tactile allodynia/thermal hypersensitivity, but
failed to impact upon later neuropathic pain once dis-
continued and failed to impact upon microglial num-
bers. Therefore, the CB1 agonists transiently benefitted
a developing or pre-existing neuropathic pain state in
this model of diabetic peripheral neuropathy. It was
anticipated that nabilone, a CB1 and CB2 receptor ago-
nist may impact upon the development of neuropathic
pain, but it was only associated with transient improve-
ment in neuropathic pain parameters.
Microglial Activation
Microglia, functionally equivalent to peripheral macro-
phages, entangle with central neurons and play a key
role in pathophysiological pain [45]. Activation of spinal
microglia can be observed in a number of neuropathic
pain models following peripheral nerve injury [5,7]. It
has been demonstrated that intrathecal delivery of
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Page 12 of 22Figure 6 Tactile (A) and thermal (B) sensory testing data for diabetic mice receiving either intranasal or intraperitoneal SR144528 at
low, medium, or high dose, with comparison to non-diabetic mice and saline delivery. There were no effects upon either tactile allodynia
or thermal hyperalgesia development or maintenance in any group at any dose (non-matched ANOVA tests, p NS). [n = 4-10 mice in each
mouse cohort for each time point].
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Page 13 of 22Figure 7 Tactile (A) and thermal (B) sensory testing data for mice with established diabetes receiving either intranasal or
intraperitoneal cannabidiol or SR144528 at low high dose, with comparison to non-diabetic mice receiving intranasal or
intraperitoneal saline. There were no effects upon either tactile allodynia or thermal hyperalgesia development or maintenance in any group at
any dose (non-matched ANOVA tests, p NS). [n = 4-10 mice in each mouse cohort for each time point] despite early intervention studies for
cannabidiol demonstrating protection against development and maintenance of neuropathic pain.
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inhibiting microglia activation, reduces the development
of induced sensory hypersensitivity in post-traumatic
nerve injury models [46,47]. CB2 agonists also appear to
limit microglia accumulation and activation in a murine
chronic neuropathic pain state.
The signal by which nerve injury or disease may lead
to microglial activation is unclear, but may relate to
acute release of ERK, an enzyme that plays a critical
role in intracellular signal transduction and neuronal
plasticity. When ERK activates within damaged neurons,
it may set into motion a series of neuronal changes that
lay the foundations for altered sensory processing [48].
In the hours following an acute injury, ERK becomes
activated in surrounding microglia where it remains
active for days and weeks, upholding microglial support
of the pain phenotype. Later, activation within astrocytes
may also occur. This pattern of ERK activation following
nerve injury likely influences ionotropic channel redistri-
bution along the damaged neuron and its neurites, per-
haps contributing to hypersensitive behaviors [48]. An
example of this is the increased expression of Nav1.3
channels within second-order spinal cord dorsal horn
neurons and third-order thalamic neurons after trau-
matic nerve injuries; these likely contribute to amplifica-
tion of hyperexcitability and unfortunate maintenance of
the pain state [16]. In addition, integrative functions,
such as signal gating [49,50], within the dorsal horn
modulate sensory signals on their travels from the per-
ipheral nervous system to the brain. Modifications in
ERK and channel function may lead to in appropriate
amplification of signals, contributing to central sensitiza-
tion. Another marker of microglial activation, increased
phosphorylation of the p38 MAPK [14] was also
observed in spinal microglia following development of
diabetes during a chronic neuropathic pain state. Pre-
vious shorter duration studies of diabetes in rats [3]
were not able to demonstrate change in the levels of
p38 MAPK phosphorylation in the spinal cords [15].
Such changes in p38 MAPK phosphorylation seem to be
limited to microglia, [51] which demonstrate substantial
increased expression, and occur across many painful
conditions[52].
Microglial Activation in Diabetes
In addition to acute traumatic injury models, diabetic
mice also exhibit enhanced microglial cell densities in
the dorsal horn of the spinal cord, accompanied by
some mild qualititative morphological changes, felt to be
related to diabetic peripheral neuropathy pain. Morpho-
logical changes similar to ours reported here have been
demonstrated in four week STZ-induced diabetic rats
[15]. In our model, there is no acute or sudden injury to
t h en e r v o u ss y s t e ma sw i t hat r a u m a t i cn e r v ei n j u r y
model, so diabetes seemed to lead to a more gradual
rise in microglia and p-p38 MAPK elevation than seen
in other models. It appears as though with progression
of the disease, enhanced p38 phosphorylation occurs
within months, but then may wane in the late time
points of our murine diabetic model. This rise and fall
Table 3 Quantitative and qualitative analysis of microglia
density within the dorsal horn and thalamus with
cannabinoid interventions
Mouse Cohort Microglial Density (number/mm
2)
Ventral Lumbar Spinal Cord Thalamic Nuclei
Non-Diabetic
Intraperitoneal
Saline 147.3 ± 17.2 (-) 99.2 ± 9.9 (-)
Intranasal
Saline 136.1 ± 19.2 (-) 105.3 ± 9.3 (-)
Diabetic
Intraperitoneal
Early Intervention
Cannabidiol 228.6 ± 15.3* (+) 116.5 ± 9.4 (+/-)
SR144528 316.6 ± 17.8 (+) 127.5 ± 11.3 (+/-)
Nabilone 309.3 ± 18.2 (+) 125.6 ± 10.5 (+/-)
WIN55212-2 305.7 ± 20.5 (+) 124.4 ± 9.7 (+/-)
SR141716A 314.7 ± 16.9 (+) 130.0 ± 10.4 (+/-)
Late Intervention
Cannabidiol 314.2 ± 18.8 (+) 118.2 ± 10.8 (+/-)
SR144528 312.5 ± 19.4 (+) 125.6 ± 9.5 (+/-)
Nabilone 319.5 ± 19.9 (+) 124.5 ± 9.2 (+/-)
WIN55212-2 311.3 ± 18.9 (+) 131.2 ± 11.2 (+/-)
SR141716A 325.3 ± 17.7 (+) 129.0 ± 9.0 (+/-)
Intranasal
Early Intervention
Cannabidiol 209.5 ± 14.8* (+) 114.7 ± 12.2 (+/-)
SR144528 302.3 ± 18.2 (+) 125.4 ± 11.3 (+/-)
Nabilone 301.1 ± 16.5 (+) 132.5 ± 11.7 (+/-)
WIN55212-2 319.1 ± 18.4 (+) 126.1 ± 8.9 (+/-)
SR141716A 316.3 ± 17.8 (+) 130.5 ± 9.6 (+/-)
Late Intervention
Cannabidiol 314.5 ± 18.1 (+) 120.0 ± 9.5 (+/-)
SR144528 322.6 ± 20.5 (+) 133.4 ± 11.6 (+/-)
Nabilone 328.1 ± 19.9 (+) 125.6 ± 11.1 (+/-)
WIN55212-2 321.1 ± 18.0 (+) 122.0 ± 9.0 (+/-)
SR141716A 312.6 ± 18.4 (+) 124.6 ± 9.4 (+/-)
All measures are mean +/- SEM for microglial densities. *indicates significance
at p < 0.05 with comparison of diabetic mice cohort groups receiving high and
low dose cannabidiol through either intranasal or intraperitoneal routes (non-
matched ANOVA tests, F-values range between 1.89-3.92 for indicated groups
and time points, DF ≥ 7,4, n ≥ 4 at each time point. Microglial activation is
indicated using a qualitative scale: - for baseline staining; + for mild response;
and ++ for moderate response, with the statistical mode response indicated in
brackets, or where two values were similar, the greater response is shown in
front of the second most common value.
Toth et al. Molecular Pain 2010, 6:16
http://www.molecularpain.com/content/6/1/16
Page 15 of 22of p-p38 MAPK expression also parallels microglial den-
sity fluctuations. Although more easily detected in acute
injury models, this greater duration of time to achieve
microglial density increases and activation may also pro-
vide a greater window for therapeutic management. It
m a ya l s ob ep o s s i b l et om o d u l a t ep 3 8M A P Kt oc o n t r i -
bute to antinociceptive effects [14,46], although this may
also affect glycemic levels, confounding the purported
mechanism by which p38 MAPK may affect nociception.
T h ed i a b e t i cm o u s em o d e lu s e ds h o w e dl a t e n c yt o
onset of neuropathic pain features and late resolution of
allodynia and hyperpathia with replacement by anesthe-
sia. Although this latency in NeP onset may be due to
gradual accumulation and activation of microglia, other
mechanisms are likely contributory as well. Central sen-
sitization with activity-dependent changes in synaptic
activity at the dorsal horn and other central nervous sys-
tem structures likely develop [53]. Ectopic activity
occurring due to excessive activity in voltage gated cal-
cium and sodium channels also contributes to sensitiza-
tion [54,55]. Time-dependent trafficking of receptors or
ion channels may also have delayed onset with pro-
longed effects. After prolonged diabetes, human DPN
patients may have remission of associated NeP [56]
similar to the phenomenon seen in our model - this
may be due to the more complete loss of intraepidermal
n e r v ef i b e r sa tt h i st i m ew i t n e s s e di nm u r i n em o d e l so f
DPN [38]. Overall, the STZ mouse model used provides
a good approximation of human diabetic neuropathy,
justifying its study for pathogenesis of NeP.
Cannabinoids and Their Receptors
Cannabinoids have a diverse range of effects on the cen-
tral nervous system, mediated by the activation of the
CB receptors coupled to G-proteins ligated by endogen-
ous ligands, the endocannabinoids. The endocannabi-
n o i d sh a v eau n i q u em o d eo fa c t i o n ,w i t hr e t r o g r a d e
synaptic inhibition of the release of neurotransmitters
such as glutamate [57]. CB2 receptors are associated
with immune cells, microglia and have been identified
in the peripheral nervous system. CB2 agonists success-
fully modulate inflammatory responses [58]. Both CB1
and CB2 receptors are expressed in activated microglial
cells, but their cellular localization differs. Modifications
in the cellular localization of CB receptors are associated
with a change in their functionality, particularly with
CB2 receptors [59], suggesting that functionality is regu-
lated by plasmalemma translocation. Such changes may
Figure 8 After several months of diabetes, microglia accumulation can be noted within dorsal spinal cord and to a lesser degree
within thalamic nuclei. Compared to non-diabetic age-matched mice (A), immunohistochemistry identified a mild but significant accumulation
of microglia within the thalamus after 5 months of diabetes (B). Microglial accumulation and activation (evaluated qualitatively) was more
substantial in the dorsal spinal cord of diabetic mice. Treatment with intranasal high dose cannabidiol (C) attenuated the microglial
accumulation identified in age-matched diabetic mice reciving no intervention (D) or receiving intranasal (E) or intraperitoneal (F) WIN55212-2
(see Tables 2 and 3). Bar = 50 μm
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tors abundantly accumulate at the leading edges of acti-
vated microglia [26]. There is certainly an inflammatory
component in neuropathic pain models, although it is
not yet understood if ongoing inflammation or inflam-
matory mediators maintain chronic neuropathic pain.
The microglial accumulation in the dorsal spinal cord in
our experiments indicates that such changes also occur
in prolonged diabetes. After 8 months of diabetes in our
murine model, microglial numbers began to fall, so neu-
roinflammation in a chronic pain model may peak
before waning after a lengthy duration. The pro-inflam-
matory actions of glia are involved in neuropathic
hypersensitivity [7], and the anti-inflammatory effects of
CB2 agonists had a central role in our study in the pre-
vention of neuropathic pain development.
T h e r ei sal a r g eb o d yo fe v i d e n c et h a tc a n n a b i n o i d s
are effective analgesics in pain, including forms of acute
pain, inflammatory pain and neuropathic pain [60]. Pre-
vious studies with CB2 agonists have demonstrated
development of anti-nociception [61]. Selective CB2
agonists modulate tactile allodynia in nerve injured rats
and mice [62], and a CB2 agonist was also of benefit in
our model of chronic diabetes and diabetic peripheral
neuropathy. CB2-mediated antinociception also occurs
in inflammatory hyperalgesia and acute nociception
Figure 9 Tactile (A) and thermal (B) sensory testing data for diabetic mice receiving either intranasal or intraperitoneal nabilone at
low, medium, or high dose, with comparison to non-diabetic mice and saline delivery is shown. Those diabetic mice receiving medium
or high doses of intranasal or intraperitoneal nabilone had amelioration of both tactile allodynia and thermal hyperalgesia beginning at week 7
when nociceptive behaviors began. This protection against the development of the neuropathic pain state disappeared after discontinuation of
nabilone at week 14. Tactile (C) and thermal (D) sensory testing data for mice with diabetes receiving either intranasal or intraperitoneal
WIN55212-2 at low, medium, or high dose, with comparison to non-diabetic mice receiving intranasal or intraperitoneal saline is also
demonstrated. Those diabetic mice receiving high doses of intranasal or intraperitoneal WIN55212-2 had amelioration of tactile allodynia
beginning at week 7 when nociceptive behaviors began, while thermal hyperalgesia was modulated by either medium or high doses of
intranasal or intraperitoneal WIN55212-2. This protection against the development of the neuropathic pain state disappeared after
discontinuation of nabilone at week 14, after which all diabetic mouse cohorts had comparable levels of tactile allodynia and thermal
hyperalgesia. For both tactile (A, C) and thermal (B, D) testing, significant differences were detected between the diabetic mouse group
receiving medium (g) or high doses (θ) of intranasal nabilone/WIN55212-2 or medium () high (Ψ) doses of intraperiteonal nabilone/WIN55212-2
when compared to the diabetic mouse group receiving low dose intranasal or intraperitoneal nabilone/WIN55212-2 respectively (non-matched
ANOVA tests, F-values range between 0.76-3.07 for indicated groups and time points, n ≥ 4, p < 0.05). Area under the curve (AUC)
measurements were also significantly different in each case (p < 0.05) for weeks 1-13, but not for assessment of tactile allodynia in mice
receiving any dose/route for WIN55212-2 (C). [n = 4-10 mice in each mouse cohort for each time point]
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Page 17 of 22Figure 10 Tactile (A) and thermal (B) sensory testing data for mice with established diabetes receiving either intranasal or
intraperitoneal cannabinoid agents, with comparison to non-diabetic mice and saline delivery. Diabetic mice receiving medium and high
doses of intranasal nabilone or WIN55212-2 had improvement of thermal hyperalgesia +/- tactile allodynia beginning at week 13 when
interventions began. Stoppage of cannabinoid agents saw resumption of the full neuropathic pain state at week 21. For both tactile (A) and
thermal (B) testing, significant differences were detected between the diabetic mouse group receiving moderate (g) or high doses (θ)o f
intranasal cannabidiol or medium (c) or high (τ) doses of intraperiteonal cannabidiol when compared to the diabetic mouse group receiving
low dose intranasal or intraperitoneal cannabidiol at outset respectively (non-matched ANOVA tests, F-values range between 0.95-2.85 for
indicated groups and time points, n ≥ 4, p < 0.05). Area under the curve (AUC) measurements were also significantly different between the
same comparison groups in each case (p < 0.05). [n = 4-10 mice in each mouse cohort for each time point]
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Page 18 of 22Figure 11 During 5 months of diabetes, Western blotting (A) identified mild increased levels of Iba1 (B) in diabetic mice.A sw e l l ,
phosphorylated p38 MAPK was elevated during diabetes at 5 months of time (C). Sample protein blots are demonstrated in A (total of 3
sample blots identified for each marker and each intervention at the final time point). Only intranasal or intraperitoneal cannabidiol administered
at the onset of diabetes was associated with suppression of Iba1 and phosphorylated p38 MAPK levels at endpoint (B, C). Multiple ANOVA tests
were performed in each case, with *indicating significant difference (p < 0.05) between diabetic cohorts receiving intranasal cannabidiol and no
intervention after 5 months of diabetes.
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Page 19 of 22[61,63,64] as well as in more chronic diseases such as
with experimental diabetes [65]. The mechanism by
which CB2 receptor agonists modulate neuropathic pain
is uncertain, but is likely to be related to inhibition of
inflammatory cell activity. Neuropathic pain requires
ongoing sensitization due to a constant afferent bom-
bardment emenating from the injured nervous system
[66] or changes in the dorsal root ganglion such as with
sympathetic sprouting [67]. Cannabinoids may suppress
such ectopic input and alter central sensitization by
modifying inflammatory activity at the site of nervous
system injury. It is entirely possible that other CB2-
mediated mechanisms exist as well. In our study, it was
only the selective CB2 agonist which led to diminished
microglial densities and p-p38 MAPK expression within
t h ed o r s a ls p i n a lc o r d ,a s s o ciated with at least partial
protection against development of neuropathic pain
even after the CB2 agonist was withdrawn. This effect
can be antagonized by concurrent CB2 antagonists [62]
or selective CB1 antagonists [68] in some studies. It was
somewhat unanticipated in our results that the CB2
antagonist and the CB1 antagonist were not pronocicep-
tive; similar results have been demonstrated in traumatic
nerve injury models of neuropathic pain [69]. This lack
of effect may have been related to insufficient dosing or
choice of delivery routes. The lack of effect of both CB1
and CB2 antagonists may also relate to persistant tonic
activity in the endogenous cannabinoid system [60].
Intranasal Delivery for Painful States
Although intranasal delivery has been initiated for
potential therapy of cognitive dysfunction, ischemic dis-
ease, or demyelinating diseasethe use of intranasal agent
delivery for pain management has been limited to the
use of fentanyl [70] and ketamine [71]. These results
demonstrate that in mice, intranasal delivery of cannabi-
noid agents is at least as effective as intraperitoneal
delivery. Future human studies may assist in the further
assessment of the roles of cannabinoids in chronic pain
prevention and alleviation.
Limitations of the Present Study
There are limitations to the present study that require
discussion. It is possible that the response to different
acute or chronic nociceptive stimuli such as tactile and
thermal stimuli may not involve cannabinoid-sensitive
peripheral components. Our investigations were limited
to specific agonists and antagonists at three doses, but
other cannabinoid agonists/antagonists and doses may
lead to different behavioural and inflammatory results
than presented here. Concentrations selected for use
were based upon prior publications and may not have
been most optimal for calculation of intranasal dosing,
although our selected doses were associated with
definite behavioural changes. Although we describe dia-
betic peripheral neuropathy pain as the main stimulus
for migroglial density increases, it is conceivable that
diabetes itself could lead to the changes.
Conclusions
The present data confirm the efficacy of cannabinoid
agonists, both for the CB1 and CB2 receptor, in modu-
lation of acute thermal and tactile hypersensitivity as
features of neuropathic pain. Furthermore, CB1 agonism
from the onset of the offending stimulus (diabetes) nor-
mally leading to neuropathic pain ameliorated the devel-
opment of a neuropathic pain state. In contrast, we did
not demonstrate worsening of the neuropathic pain
state with CB1 or CB2 antagonists. Overall, this suggests
a greater role for CB2 receptors in neuropathic pain,
including a chronic diabetic peripheral neuropathy state,
than has previously been described. Such selective tar-
geting with either CB2 selective agonists may play a role
in the prevention of neuropathic pain states if treatment
could be delivered at the time of neural injury or
disease.
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